Advanced search
Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 32, 2008 - Issue 6
Submit an article Journal homepage
584
Views
16
CrossRef citations to date
0
Altmetric
Response to the Letter to the Editor

Transparency and Access to Full Information for the Fatal or Serious Toxicity Risks, Low Efficacy and High Price of Deferasirox, Could Increase the Prospect of Improved Iron Chelation Therapy Worldwide

George J. Kontoghiorghes Postgraduate Research Institute Science, Technology, Environment an Medicine, Limassol, CyprusCorrespondence[email protected]
Pages 608-615 | Received 24 Apr 2008, Published online: 07 Jul 2009

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (11)

Christina N Kontoghiorghe & George J Kontoghiorghes. (2016) Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy 10, pages 465-481.
Read now
Ali T Taher, John B Porter, Antonis Kattamis, Vip Viprakasit & M Domenica Cappellini. (2016) Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy 10, pages 4073-4078.
Read now
George J Kontoghiorghes. (2013) A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?. Expert Opinion on Drug Safety 12:5, pages 605-609.
Read now
George J. Kontoghiorghes. (2011) A Record Of 1320 Suspect, Deferasirox-Related, Patient Deaths Reported In 2009: Insufficient Toxicity Testing, Low Efficacy And Lack Of Transparency May Endanger The Lives Of Iron Loaded Patients. Hemoglobin 35:3, pages 301-311.
Read now
George J Kontoghiorghes. (2011) The Proceedings Of The 19Th International Conference On Chelation Held In London, United Kingdom: Major Changes In Iron Chelation Therapy In The Last 25 Years Using Deferiprone (L1) Has Resulted In The Complete Treatment Of Iron Overload. Hemoglobin 35:3, pages 181-185.
Read now
Rebecca J. Abergel & Kenneth N. Raymond. (2011) Multidentate Terephthalamidate and Hydroxypyridonate Ligands: Towards New Orally Active Chelators. Hemoglobin 35:3, pages 276-290.
Read now
George J Kontoghiorghes. (2010) Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opinion on Drug Safety 9:4, pages 633-641.
Read now
George J. Kontoghiorghes, Aspasia Spyrou & Annita Kolnagou. (2010) Iron Chelation Therapy in Hereditary Hemochromatosis and Thalassemia Intermedia: Regulatory and Non Regulatory Mechanisms of Increased Iron Absorption. Hemoglobin 34:3, pages 251-264.
Read now
G J Kontoghiorghes, A Kolnagou, C-T Peng, S V Shah & A Aessopos. (2010) Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opinion on Drug Safety 9:2, pages 201-206.
Read now
George J. Kontoghiorghes. (2009) A New Era in Iron Chelation Therapy: The Design of Optimal, Individually Adjusted Iron Chelation Therapies for the Complete Removal of Iron Overload in Thalassemia and other Chronically Transfused Patients. Hemoglobin 33:5, pages 332-338.
Read now
Su-Peng Yeh, Yang-Sheng Yang, Chao-Yuan Yao & Ching-Tien Peng. (2009) Iron Chelation Therapy for Patients with Myelodysplastic Syndrome. Hemoglobin 33:5, pages 339-345.
Read now

Articles from other publishers (5)

George J. Kontoghiorghes. (2021) Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs. Medicines 8:7, pages 36.
Crossref
Christina N Kontoghiorghe. (2014) World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World Journal of Methodology 4:3, pages 163.
Crossref
Gérard Lescoat, Stéphane Léonce, Alain Pierré, Lucie Gouffier & François Gaboriau. (2012) Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures. Chemico-Biological Interactions 195:2, pages 165-172.
Crossref
Efthimia VlachakiK. Chatzinikolaou, E. Bekiari, F. Klonizakis & A. Tsapas. (2011) Is Deferasirox Implicated in Multiple Organ Failure in a Patient With Homozygous β-Thalassemia?. Angiology 62:4, pages 346-348.
Crossref
R.H.B. Meyboom. 2011. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 465 478 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.